Guideline-Based Screening for Cardiac Amyloidosis in Older Patients With Left Ventricular Hypertrophy
A cross-sectional study from Moscow examined how often cardiac amyloidosis may be present in older cardiac patients with left ventricular hypertrophy when a predefined diagnostic pathway is applied to every eligible patient. The clinical question is tightly focused and highly practical: among older adults already carrying a structural heart diagnosis, how many may actually have a protein-misfolding cardiomyopathy rather than hypertensive remodeling, hypertrophic cardiomyopathy, or heart failure with preserved ejection fraction?
The study was conducted at a single centre in Russia and used a guideline-based diagnostic algorithm for all consecutive participants. Patients were included regardless of whether they had heart failure, which broadens the clinical lens beyond the familiar decompensated inpatient presentation. That choice matters because cardiac amyloidosis often surfaces only after years of nonspecific symptoms, when patients have already accumulated labels such as HFpEF or unexplained hypertrophy. In routine practice, those labels can delay the recognition of an infiltrative disorder that carries distinct prognostic and therapeutic implications.
Cardiac amyloidosis itself arises from misfolded proteins depositing insoluble fibrils in the myocardium, gradually impairing organ function. Two dominant forms drive most of the cardiac burden: AL amyloidosis, caused by monoclonal immunoglobulin light chains, and ATTR amyloidosis, caused by transthyretin misfolding. Each behaves differently at the bedside. AL disease can progress quickly and demands urgent hematologic evaluation, while ATTR amyloidosis is often more indolent but still produces substantial morbidity, restrictive physiology, and progressive heart failure. Both can look deceptively similar on echocardiography and clinical examination.
The study sits in an important diagnostic gap. Older adults with increased ventricular wall thickness often enter care through the lens of common disease: longstanding hypertension, a presumed hypertrophic phenotype, or unexplained dyspnea attributed to age and diastolic dysfunction. When amyloid infiltration is the true substrate, wall thickness is not the whole story. The myocardium becomes stiff, filling pressures rise, and symptoms can resemble HFpEF even when the underlying pathology is entirely different. That overlap explains why a structured algorithm is so valuable; it forces clinicians to move beyond surface anatomy and ask what is driving the hypertrophy.
A single-sentence reality governs this disease: missing amyloidosis means missing a distinct cardiomyopathy with a different trajectory.
Why the Moscow Cohort Matters for Everyday Cardiology
The investigators framed the work against a backdrop of increasing life expectancy in Russia and the parallel rise of age-related diseases, including cardiac amyloidosis. As populations age, the pool of patients with unexplained ventricular thickening, heart failure symptoms, and mixed comorbidity profiles grows larger. In that setting, amyloidosis is not rare because it is exotic; it is rare because it is overlooked.
The study’s design reinforces that point. Applying the same diagnostic algorithm to every consecutive participant reduces the risk that clinicians selectively test only the most obvious cases. Including patients irrespective of heart failure status also makes the cohort more representative of the broad outpatient and inpatient population in which amyloidosis hides. In real terms, some patients with infiltrative disease are not yet in overt congestion or advanced decompensation. They may present with modest exercise intolerance, atrial arrhythmias, conduction disease, or simply increased wall thickness on imaging. A screening strategy that waits for advanced heart failure will inevitably miss earlier disease.
The article’s stated strengths are straightforward and clinically relevant. The algorithm was predefined and grounded in guidelines, which helps standardize case detection. Consecutive enrollment limits cherry-picking. The limitations are just as direct: the investigation was single-centre and the sample size was relatively small, both of which restrict generalisability. Those constraints do not weaken the clinical rationale; they define the first step in a region where diagnostic pathways for amyloidosis may still be unevenly deployed.
The excerpt provided does not include the numerical prevalence estimate or the final diagnostic breakdown. Even without those figures, the clinical message remains clear from the study design alone: older patients with left ventricular hypertrophy deserve systematic evaluation for amyloid disease when the phenotype does not fit neatly into common explanations. The reason is biological as much as epidemiologic. Amyloid fibrils distort ventricular compliance, impair diastolic filling, and can produce a restrictive physiology that standard heart failure pathways may not fully address. In AL amyloidosis, that burden can accelerate rapidly; in ATTR disease, cumulative deposition can quietly erode cardiac reserve over time.
Diagnostic Delay Still Starts With Misclassification
Cardiac amyloidosis is frequently under-recognised because its presentation overlaps with disorders cardiologists see every day. Hypertrophic cardiomyopathy, hypertensive heart disease, and HFpEF all share pieces of the phenotype, especially when wall thickness is increased and symptoms are nonspecific. That diagnostic ambiguity is exactly where a guideline-based algorithm earns its value. It structures suspicion, prioritises appropriate testing, and reduces the risk that infiltrative disease is dismissed as a routine aging-related change.
For clinicians, the practical implication is not to treat every patient with left ventricular hypertrophy as if amyloidosis is present. It is to recognise which patients merit deliberate screening rather than assumption. Older age, cardiac structural abnormalities, and unexplained symptoms create the clinical terrain in which amyloid disease can be concealed. In that context, a systematic approach can change the entire diagnostic sequence, from echo findings to tissue confirmation and subtype assignment.
The Moscow cohort also points to a broader research need. Small single-centre studies are useful for estimating the local burden of disease and for testing whether a structured diagnostic pathway can be operationalised in routine care. Larger multicentre cohorts will be needed to establish how often cardiac amyloidosis is uncovered in similar populations across different health systems and referral settings. For now, this study adds another reminder that ventricular hypertrophy in an older patient is a pattern, not a diagnosis, and the differential should remain open until infiltrative disease has been considered and, when indicated, actively pursued.